What is HC Wainwright's Forecast for MIST FY2029 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $1.86 for the year. HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals' current full-year earnings is ($0.62) per share.

Milestone Pharmaceuticals Stock Down 2.0 %

NASDAQ MIST traded down $0.04 during mid-day trading on Tuesday, reaching $1.98. 991,733 shares of the company's stock traded hands, compared to its average volume of 630,631. The company has a market cap of $105.59 million, a price-to-earnings ratio of -2.44 and a beta of 1.78. The company has a fifty day simple moving average of $1.97 and a 200-day simple moving average of $1.67. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Valeo Financial Advisors LLC grew its position in shares of Milestone Pharmaceuticals by 100.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company's stock worth $30,000 after acquiring an additional 10,000 shares in the last quarter. PVG Asset Management Corp bought a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth approximately $46,000. Atria Investments Inc lifted its holdings in shares of Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company's stock worth $61,000 after purchasing an additional 12,430 shares during the last quarter. Finally, BML Capital Management LLC lifted its holdings in shares of Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company's stock worth $1,727,000 after purchasing an additional 33,196 shares during the last quarter. Institutional investors and hedge funds own 86.18% of the company's stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.